ARTICLE | Company News
Santhera, BioLineRx in deal for MC4R antagonists
October 15, 2010 12:45 AM UTC
Santhera Pharmaceuticals Holding AG (SIX:SANN) granted BioLineRx Ltd. (Tel Aviv:BLRX) exclusive rights to develop, sublicense and commercialize preclinical melanocortin 4 receptor (MC4R) antagonists, ...